课题基金 / 基金详情

NKT cells as modulators of AIDS vaccine efficacy

NKT cells as modulators of AIDS vaccine efficacy
NKT 细胞作为艾滋病疫苗功效的调节剂
批准号:
9022675
负责人:
Amitinder Kaur
金额:
$69.06万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-06-19 至 2016-05-31

项目摘要

项目成果

Amitinder Kaur的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):艾滋病流行三十年来,全球估计有3400万艾滋病毒感染者,其中近70%居住在撒哈拉以南非洲。尽管为研制艾滋病疫苗而进行的深入研究仍在继续,但目前还没有研制出有效的艾滋病毒疫苗。对于成功的HIV疫苗,人们普遍认为它应该能够诱导粘膜免疫,引发有效的细胞溶解和多功能HIV特异性T细胞反应,以及具有广泛定向中和活性和抗体依赖性细胞毒性(ADCC)活性的抗HIV抗体。先天免疫系统是适应性免疫的重要调节剂,可以在全身和粘膜部位形成病原体特异性免疫反应的大小、质量和持久性。自然杀伤T细胞(NKT)是先天免疫系统中独特的T细胞,具有强大的免疫调节特性,可以影响T细胞和B细胞免疫。在这项拨款申请中,我们建议使用SIV感染猕猴模型来研究NKT激活将提高疫苗免疫原性和提高疫苗介导的对SIV感染的获得和控制的保护的假设。相反,NKT细胞的缺失可能降低保护性减毒SIV活疫苗(LASIV)的效力。我们的具体目标是:第一。确定体内给药nkt消耗型和nkt激活型单克隆抗体的最佳给药方案,并表征它们在食蟹猴血液和组织中的作用。# 2。研究NKT激活的佐剂效应将增强重组Ad26/Ad5-SIV疫苗方案的保护效果的假设。# 3。研究假设在NKT耗尽的情况下接种疫苗将取消高度保护性LASIV疫苗的保护功效。
英文摘要
DESCRIPTION (provided by applicant): Thirty years into the AIDS epidemic, there are an estimated 34 million HIV-infected people worldwide and almost 70% reside in sub-Saharan Africa. Although intensive research towards developing an AIDS vaccine is continuing, there are as yet no effective HIV vaccines on the horizon. For a HIV vaccine to be successful, it is widely accepted that it should be able to induce mucosal immunity, elicit an effective cytolytic and polyfunctional HIV-specific T cell response along with anti-HIV antibodies that have broadly directed neutralization activity and antibody dependent cellular cytotoxicity (ADCC) activity. The innate immune system is an important modulator of adaptive immunity and can shape the magnitude, quality, and durability of pathogen-specific immune responses at systemic and mucosal sites. Natural killer T (NKT) cells are unique T cells of the innate immune system with potent immunoregulatory properties that can impact T and B cell immunity. In this grant application we propose to use the SIV infection macaque model to investigate the hypothesis that NKT activation will improve vaccine immunogenicity and improve vaccine-mediated protection against acquisition and control of SIV infection. Conversely, the absence of NKT cells may reduce the efficacy of a protective live attenuated SIV (LASIV) vaccine. Our specific aims are: #1. Determine the optimal dosing regimen for in vivo administration of the NKT-depleting and NKT-activating mAbs and characterize their effect in blood and tissues of cynomolgus macaques. #2. Investigate the hypothesis that the adjuvant effect of NKT activation will enhance the protective efficacy of a heterologous prime-boost recombinant Ad26/Ad5-SIV vaccine regimen. #3. Investigate the hypothesis that vaccination in the setting of NKT depletion will abrogate the protective efficacy of a highly protective LASIV vaccine.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of maternal-fetal interface NK cells in pregnancy maintenance and congenital CMV transmission
Role of maternal-fetal interface NK cells in pregnancy maintenance and congenital CMV transmission
CMV infection impact on placental immunometabolism and fetal immunity
  • 批准号:
    10536197
  • 项目类别:
  • 资助金额:
    $42.47万
  • 财政年份:
    2022
  • 负责人:
    Amitinder Kaur
  • 依托单位:
NKT cells as modulators of AIDS vaccine efficacy
  • 批准号:
    8846538
  • 项目类别:
  • 资助金额:
    $79.49万
  • 财政年份:
    2012
  • 负责人:
    Amitinder Kaur
  • 依托单位:
国内基金
海外基金
分化肌细胞脱细胞ECM-cells sheet 3D 支架构建及其促进容积性肌组织缺损再 生修复应用及机制研究
糖尿病ED中成纤维细胞衰老调控内皮细胞线粒体稳态失衡的机制研究
  • 批准号:
    82371634
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    赵福军
  • 依托单位:
Got2基因对浆细胞样树突状细胞功能的调控及其在系统性红斑狼疮疾病中的作用研究
  • 批准号:
    82371801
  • 项目类别:
    面上项目
  • 资助金额:
    47.00万元
  • 批准年份:
    2023
  • 负责人:
    周海波
  • 依托单位:
脐带间充质干细胞微囊联合低能量冲击波治疗神经损伤性ED的机制研究
  • 批准号:
    82371631
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2023
  • 负责人:
    卢慕峻
  • 依托单位: